First Ever Needle-Free Treatment Option Against Anaphylaxis Approved by FDA

The FDA has granted approval for Neffy, the first needle-free treatment option for anaphylaxis, a severe allergic reaction. This nasal spray alternative to EpiPens also contains the epinephrine used in fight-or-flight responses to rapidly open airways and elevate blood pressure by constricting blood vessels during such reactions. The new device introduces a breakthrough by addressing the unmet need for a needleless option, aiming to reduce barriers to quick treatment. This is prepared by SSP.

According to ARS Pharma's CEO Richard Lowenthal, Neffy is designed to be more user-friendly and accessible compared to auto-injectors, which have faced supply and design issues. The spray can be administered in one nostril for adults and children over 66 pounds, with an additional dose available if symptoms persist. Notably, the treatment costs are expected to be competitive, promising affordability with commercial insurance co-pays potentially as low as $25.

Though specific challenges like a history of nasal surgery might affect the drug's absorption, consultation with a healthcare provider is advised for such cases. Neffy's approval follows rigorous study, demonstrating similar efficacy to traditional epinephrine injectors, offering an easy-to-use alternative validated through several clinical trials.

Ultimately, Neffy hopes to eliminate the complications previously linked to the distribution and use of epinephrine auto-injectors, providing a viable, less invasive solution for those experiencing anaphylaxis.